Simon Mitchell

Dr Simon Mitchell advises a growing number of direct multinational clients and significant foreign attorney firms in respect of patent application drafting, filing and prosecution, registered design filing and prosecution, contentious matters (e.g. oppositions, revocations) and advisory work.

His expertise focuses in the fields of human health, animal health and food security, and includes biotechnological, chemical and mechanical inventions. Specific areas of life sciences expertise include medicinal chemistry; biologics such as therapeutic peptides and proteins, including vaccines and antibodies; diagnostic methods; oligonucleotide therapeutics and probes for diagnosis and treatment, e.g. siRNA, miRNA; genetically-encoded reporter and cell-sorting systems; stem cells; microbiome-related inventions; medical devices; agriculture; and plant varieties.

Simon’s human and animal health patent cases include those relating to cancer, pain, inflammation, infection, epilepsy, migraine, tinnitus, diabetes, multiple sclerosis, Parkinson’s disease, respiratory diseases, eye disorders, genetics-based diagnostics and treatments, sea lice treatments and digestive disorders.

Before joining the profession, Simon worked as postdoctoral researcher at University College London, the Biochemistry Department of Cornell Medical College in New York and the Medical Research Council Laboratory of Molecular Biology in Cambridge, UK.

The focus of his academic research was the pharmacology, biophysics and biochemistry of synaptic transmission, which used electrophysiological, mechano-optical-photonic, genetic, biochemical and computational methods. His research was published in high-profile journals such as Nature, Nature Neuroscience, Neuron and the Journal of Neuroscience.

Simon is recommended in the Legal 500 2017. Simon was singled out for “in-depth scientific knowledge, pragmatic advice and flexibility”, as part of a patent team praised for its “ability and willingness to dedicate resource when required to support urgent issues” and for its “extremely high” level of service.

He is also recommended in the Legal 500 2018/2019, particularly in respect of his EPO opposition practice, and the IAM Patent 1000 2019 in respect of producing “flawless drafts, time and time again”.

Simon is recommended in Legal 500, IAM Patent 1000 and IP Stars.

Simon entered the profession in 2008 and joined Murgitroyd as part of the addition of UDL by Murgitroyd in October 2021. Simon leads our London Central and Cambridge Offices